重组人促红细胞生成素不同给药时间治疗早产儿贫血的疗效及对患儿输血率的影响  

Efficacy of Hemopoietin in Treatment of Anemia in Premature Infant at Different Administration Times and its Effects on Blood Transfusion Rate

作　　者：高玲[1] 徐红丹 翟慢慢[1] GAO Ling;XU Hongdan;ZHAI Manman(Dept.of Blood Transfusion,Children＇s Hospital Affiliated of Zhengzhou University,Henan Zhengzhou 450003,China)

机构地区：[1]郑州大学附属儿童医院输血科,河南郑州450003

出　　处：《中国医院用药评价与分析》2018年第7期890-891,895,共3页Evaluation and Analysis of Drug-use in Hospitals of China

摘　　要：目的:探讨重组人促红细胞生成素不同给药时间治疗早产儿贫血的疗效及对患儿输血率的影响。方法:选取2016年11月至2017年10月郑州大学附属儿童医院收治的贫血早产儿84例,按照入院顺序分组,奇数为对照组,偶数为观察组,每组42例。两组患儿出生后均给予对症治疗,其中对照组患儿于出生第3周给予重组人促红细胞生成素,观察组患儿于出生第2周给予重组人促红细胞生成素。观察两组患儿治疗前(T0)、治疗1个月(T_1)和治疗3个月(T_2)的血红蛋白(Hb)、红细胞比容(HCT)及网织红细胞计数(Ret)水平,治疗期间的输血率和不良反应发生率。结果:T_1、T_2时,两组患儿Hb、HCT水平明显降低,但观察组患儿明显高于对照组;T_1、T_2时,两组患儿Ret水平明显升高,且观察组患儿明显高于对照组,上述差异均有统计学意义(P<0.05)。治疗期间,观察组患儿的输血率为45.24%(19/42),低于对照组的57.14%(24/42),但差异无统计学意义(P>0.05);观察组患儿不良反应发生率为7.14%(3/42),略高于对照组的2.38%(1/42),但差异无统计学意义(P>0.05)。结论:早期应用重组人促红细胞生成素治疗早产儿贫血疗效显著,安全性高,但输血率仍处于较高水平。OBJECTIVE： To probe into the efficacy of recombinant human erythropoietin（ rhEPO） in treatment of anemia in premature infant at different administration times and its effects on blood transfusion rate. METHODS：84 premature infant with anemia admitted into Children＇s Hospital Affiliated of Zhengzhou University from Nov. 2016 to Oct. 2017 were according to admission order grouping,odd number as the control group,even number as the observation group,with 42 cases in each. Both groups were given symptomatic treatment after the birth,of which the control group was treated with rh EPO at the third week,while the observation group was treated with rh EPO at the second week. At before treatment（ T_0）,1 month after treatment（ T_1） and 3 months after treatment（ T_2）,the hemoglobin（ Hb）,hematocrit（ HCT） and reticulocyte（ Ret） levels,blood transfusion rates during treatmentn and incidences of adverse drug reactions of two groups were observed. RESULTS： At T_1 and T_2,the Hb and HCT levels of both groups were significantly decreased,and those of the observation group were significantly higher than the control group; at T_1 and T_2,the Ret levels of both groups were significantly increased,and that of the observation group were significantly higher than the control group,with statistically significant difference（ P〈0. 05）. During treatment,the blood transfusion rate of observation group was 45. 24%（ 19/42）,which was lower than that of the control group（ 57. 14%,24/42）,while the difference had no statistical significance（ P〉0. 05）; the incidence of adverse drug reactions of observation group was 7. 14%（ 3/42）,which was slightly higher than that of the control group（ 2. 38%,1/42）,while the difference had no statistical significance（ P〉0. 05）. CONCLUSIONS： Efficacy of rhEPO in treatment of anemia in premature infant at early stage is remarkable,with high safety,while the blood transfusion rate maintains a high level.

关 键 词：重组人促红细胞生成素 早产儿贫血 疗效 输血率 

分 类 号：R985[医药卫生—药品]